NEW YORK (GenomeWeb) – Danaher today said that its first quarter sales grew 5 percent year over year, while its Life Science & Diagnostics segment grew 2 percent. 

For the three months ended April 3, the Washington-based conglomerate posted sales of $4.87 billion, up from $4.66 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $4.83 billion. 

Core sales improved 5 percent year over year, while acquisitions added 6 percentage points to growth. Currency effects dampened results by 6.5 percent, the firm said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.